Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.
Nature Cell and Biostar Stem Cell Research Institute Begin World’s First Stem Cell-Based Regenerative Treatment for Alzheimer’s Disease in Japan
South Korea’s Biostar Stem Cell Research Institute – jointly operated by Nature Cell and Rbio – announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.
Alzheon, based in Framingham, Massachusetts, filed with the U.S. Securities and Exchange Commission to launch an initial public offering (IPO).
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
Chicago-based AbbVie and Cambridge, Mass.-based Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.
At the Leerink Healthcare Conference, Biogen chief medical officer Al Sandrock shook up investors by saying the company added 510 more patients to its clinical trial of aducanumab in Alzheimer’s disease.
Biogen Inc. will stop testing the company’s established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study.
ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.